BioLineRx Ltd. (BLRX) — SEC Form D Filing

BioLineRx Ltd. (BLRX) filed an SEC Form D on September 9, 2026, reporting $3.75M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
September 9, 2026
Amount reported
$3.75M
Round stage
Series B+
Industry
Biotechnology
Website
https://biolinerx.com/

What the company does

Exemption: Rule 506(b). Incorporated: ISRAEL

Problem

Patients suffer from certain cancers, rare diseases, and devastating conditions like pancreatic ductal adenocarcinoma (PDAC), for which there is a significant unmet medical need for effective treatments.

Solution

BioLineRx develops life-changing therapies, including GLIX1, an oral small molecule targeting the DNA damage response in cancer cells, and a PDAC program, to provide meaningful therapeutic benefits to patients.

Why now

Advances in understanding complex diseases like cancer and rare genetic disorders, combined with innovations in drug discovery and clinical development methodologies, create an opportune time for focused therapeutic development.

Verdict

Investors backed a targeted therapeutic approach to high-unmet-need diseases like PDAC, not a platform technology with broad applicability. This cleared because the narrative presented a clear path to de-risking specific assets within a known regulatory framework, emphasizing execution over novel science. Investors were implicitly betting on the team's ability to navigate clinical trials and demonstrate efficacy for GLIX1 and the PDAC program, which would then attract larger pharma partners. This limited upside to the value of individual drug assets rather than creating a diversified portfolio or breakthrough modality.

Source: SEC EDGAR Form D filing